A new tool to detect cancer through blood or urine samples by analyzing DNA changes
METHYL-SENTRY: Proposed feasibility study of a nanopore diagnostic tool with rapid automated measurement of cell free DNA methylation state for clinical cancer evaluation
This study is testing a new, easy way to find cancer early by looking at tiny bits of DNA in your blood or urine, which can help doctors catch cancer sooner and improve treatment outcomes.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Goeppert, LLC NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10708833 on NIH RePORTER |
What this research studies
This research investigates a novel diagnostic tool that uses nanopore technology to analyze cell-free DNA (cfDNA) for early detection of cancer. By focusing on hypermethylated biomarkers in cfDNA, the tool aims to provide a non-invasive, rapid method for identifying cancer states through blood or urine samples. The approach leverages the fact that cancer patients have a higher proportion of cfDNA from tumor cells, allowing for more accurate cancer screening. The goal is to develop a technique that can be easily implemented in clinical settings to improve patient outcomes through earlier diagnosis.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk for cancer or those experiencing symptoms suggestive of malignancy.
Not a fit: Patients with no risk factors for cancer or those who are not experiencing any symptoms may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking method for early cancer detection, significantly improving treatment outcomes.
How similar studies have performed: Previous research has shown promise in using liquid biopsies for cancer detection, indicating that this approach could be a valuable advancement in diagnostic methods.
Where this research is happening
Philadelphia, United States
- Goeppert, LLC — Philadelphia, United States (Active)
Researchers
- Principal investigator: Niedzwiecki, David John — Goeppert, LLC
- Study coordinator: Niedzwiecki, David John
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.